Last kr483.30 DKK
Change Today -6.20 / -1.27%
Volume 162.0K
COLOB On Other Exchanges
Symbol
Exchange
OTC US
Copenhagen
OTC US
Frankfurt
As of 11:05 AM 09/23/14 All times are local (Market data is delayed by at least 15 minutes).

coloplast-b (COLOB) Snapshot

Open
kr490.00
Previous Close
kr489.50
Day High
kr490.30
Day Low
kr482.20
52 Week High
06/6/14 - kr533.00
52 Week Low
09/25/13 - kr307.40
Market Cap
106.3B
Average Volume 10 Days
198.2K
EPS TTM
kr10.91
Shares Outstanding
202.0M
EX-Date
12/5/14
P/E TM
44.3x
Dividend
kr11.00
Dividend Yield
2.28%
Current Stock Chart for COLOPLAST-B (COLOB)

Related News

No related news articles were found.

coloplast-b (COLOB) Related Businessweek News

No Related Businessweek News Found

coloplast-b (COLOB) Details

Coloplast A/S develops and markets intimate healthcare products and services worldwide. The company offers ostomy care products for intestinal dysfunction resulting from disease, accident, and congenital disorder. Its ostomy care products include colostomy, ileostomy, and urostomy bags under the SenSura brand; and SenSura Mio, a colostomy product with elastic adhesive that fits individual body shapes, as well as ostomy accessories under the Brava brand. The company also provides urology care products for people suffering from diseases and symptoms of the urinary system, such as urinary incontinence, kidney stones, enlarged prostate, impotence, and pelvic floor prolapse, as well as the male reproductive system. Its disposable surgical devices include prostate catheters and stents used for urological and gynaecological applications before, during, and after surgery under the Porgès brand; vaginal slings to restore continence; synthetic mesh products to treat weak pelvic floor; and penile implants for men. In addition, the company provides continence care products comprising SpeediCath catheters that offer catherisation for both genders; and Peristeen, an anal irrigation system for controlled emptying of the bowel. Further, it offers wound care products, such as foam dressings under the Biatain brand and hydrocolloid dressing under the Comfeel brand, as well as skin care products consisting of disinfectant liquids or creams used to protect and treat the skin and to clean wounds. Additionally, Coloplast offers Interdry AG, a textile placed in a skin fold to absorb moisture for the treatment and prevention of skin fold problems, such as fungal infections, damaged skin, or odour nuisance. The company supplies its products to hospitals, institutions, wholesalers, and retailers, as well as distributes directly to consumers. Coloplast A/S was founded in 1954 and is headquartered in Humlebaek, Denmark.

8,500 Employees
Last Reported Date: 08/13/14
Founded in 1954

coloplast-b (COLOB) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr7.4M
Executive Officer
Total Annual Compensation: kr5.4M
Compensation as of Fiscal Year 2013.

coloplast-b (COLOB) Key Developments

Coloplast A/S Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2014; Provides Earnings Guidance for the Full Year of Fiscal 2014

Coloplast A/S announced unaudited consolidated earnings results for the third quarter and nine months ended June 30, 2014. For the nine months, the company announced revenue of DKK 9,214 million compared to DKK 8,665 million for the same period a year ago. Operating profit (EBIT) was DKK 2,047 million compared to DKK 2,699 million for the same period a year ago. Profit before tax was DKK 2,079 million compared to DKK 2,617 million for the same period a year ago. Net profit for the period was DKK 1,549 million compared to DKK 1,962 million for the same period a year ago. Earnings per share (EPS), diluted was DKK 7.23 compared to DKK 9.14 for the same period a year ago. Return on equity was 34% compared to 43% for the same period a year ago. Cash flows from operating activities was DKK 1,988 million compared to DKK 1,947 million for the same period a year ago. Investments in intangible assets was DKK 16 million compared to DKK 24 million for the same period a year ago. Investments in land and buildings was DKK 1 million compared to DKK 4 million for the same period a year ago. Investments in plant and machinery was DKK 53 million compared to DKK 52 million for the same period a year ago. Investments in property, plant and equipment under construction was DKK 293 million compared to DKK 215 million for the same period a year ago. Free cash flow was DKK 1,645 million compared to DKK 1,650 million for the same period a year ago. For the quarter, the company announced revenue of DKK 3,134 million compared to DKK 2,958 million for the same period a year ago. Operating profit (EBIT) was DKK 1,050 million compared to DKK 943 million for the same period a year ago. Profit before tax was DKK 1,057 million compared to DKK 930 million for the same period a year ago. Net profit for the period was DKK 788 million compared to DKK 710 million for the same period a year ago. Earnings per share (EPS), diluted was DKK 3.69 compared to DKK 3.30 for the same period a year ago. Return on equity was 52% compared to 46% for the same period a year ago. The company provided earnings guidance for the full year of fiscal 2014. The company continues to expect organic revenue growth of about 9% and of about 7% in DKK. The company continues to expect the EBIT margin before special items to be 33% to 34% at constant exchange rates and about 33% in DKK. The company continues to expect the EBIT margin to be 25% to 26% at constant exchange rates and about 25% in DKK. Capital expenditure is expected to be in the neighbourhood of DKK 500 million. The effective tax rate is still expected to be around 25%.

Coloplast A/S, Q3 2014 Earnings Call, Aug 13, 2014

Coloplast A/S, Q3 2014 Earnings Call, Aug 13, 2014

Coloplast A/S Announces Executive Changes, Effective 1 July 2014

The Board of Directors of Coloplast A/S have decided to expand the Executive Management from two to four members as of 1 July 2014. Kristian Villumsen is appointed AS Executive Vice President, Chronic Care (EVP, CC) with responsibility for Global Marketing, R&D and sales regions within ostomy – and continence care. Since joining the company in 2008, Kristian has been head of Global Marketing, Europe 11 and most recently Region Emerging Markets. Allan Rasmussen is appointed as Executive Vice President, Global Operations (EVP, GO) with responsibility of Global Operations, Procurement and Quality & Environment. Since joining the company in 1992, Allan has had a number of management assignments within production, sales and procurement. Anders Lonning-Skovgaard is appointed as Chief Financial Officer (CFO) with responsibility for Corporate Finance and Corporate IT. Since joining the company in 2006, Anders has held a commercial management position and most recently been SVP for Corporate IT.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COLOB:DC kr483.30 DKK -6.20

COLOB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $145.02 USD -2.09
Smith & Nephew PLC 1,038 GBp -30.00
St Jude Medical Inc $61.68 USD -0.72
Teleflex Inc $106.16 USD -1.36
View Industry Companies
 

Industry Analysis

COLOB

Industry Average

Valuation COLOB Industry Range
Price/Earnings 43.0x
Price/Sales 8.0x
Price/Book 17.9x
Price/Cash Flow 40.4x
TEV/Sales 7.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COLOPLAST-B, please visit www.coloplast.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.